Oxytetracycline DihydrateCAS# 6153-64-6 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 6153-64-6 | SDF | Download SDF |
| PubChem ID | 54680691 | Appearance | Powder |
| Formula | C22H28N2O11 | M.Wt | 496.46 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 5 mg/mL (10.07 mM) in DMSO | ||
| Chemical Name | (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate | ||
| SMILES | CC1(C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O.O.O | ||
| Standard InChIKey | IMLJLCJZQLGHJS-JEKSYDDFSA-N | ||
| Standard InChI | InChI=1S/C22H24N2O9.2H2O/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29;;/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31);2*1H2/t12-,13-,14+,17+,21-,22+;;/m1../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Oxytetracycline Dihydrate Dilution Calculator
Oxytetracycline Dihydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0143 mL | 10.0713 mL | 20.1426 mL | 40.2852 mL | 50.3565 mL |
| 5 mM | 0.4029 mL | 2.0143 mL | 4.0285 mL | 8.057 mL | 10.0713 mL |
| 10 mM | 0.2014 mL | 1.0071 mL | 2.0143 mL | 4.0285 mL | 5.0357 mL |
| 50 mM | 0.0403 mL | 0.2014 mL | 0.4029 mL | 0.8057 mL | 1.0071 mL |
| 100 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.4029 mL | 0.5036 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxytetracycline Dihydrate
- (+)-Nortrachelogenin
Catalog No.:BCN7020
CAS No.:61521-74-2
- Quercetin Dihydrate
Catalog No.:BCN2967
CAS No.:6151-25-3
- alpha-Mangostin
Catalog No.:BCN4138
CAS No.:6147-11-1
- Lup-20(29)-ene-2alpha,3beta-diol
Catalog No.:BCN4612
CAS No.:61448-03-1
- CIS-Resveratrol
Catalog No.:BCC8150
CAS No.:61434-67-1
- Bisabola-3,10-dien-2-one
Catalog No.:BCN7510
CAS No.:61432-71-1
- Z-D-Ala-ol
Catalog No.:BCC2589
CAS No.:61425-27-2
- 2-Amino-3-Formylchromone
Catalog No.:BCC8526
CAS No.:61424-76-8
- Carmofur
Catalog No.:BCC1214
CAS No.:61422-45-5
- Rolipram
Catalog No.:BCC2282
CAS No.:61413-54-5
- 2,4-Dihydroxyphenylacetic acid
Catalog No.:BCN4139
CAS No.:614-82-4
- 2-Hydroxycinnamic acid
Catalog No.:BCN5039
CAS No.:614-60-8
- Verbasoside
Catalog No.:BCN8197
CAS No.:61548-34-3
- L-Rhamnose
Catalog No.:BCN6302
CAS No.:6155-35-7
- Acetylatractylodinol
Catalog No.:BCN8111
CAS No.:61582-39-6
- DHBP dibromide
Catalog No.:BCC6811
CAS No.:6159-05-3
- Vasicine
Catalog No.:BCN4140
CAS No.:6159-55-3
- 15,16-Epoxy-12R-hydroxylabda-8(17),13(16),14-triene
Catalog No.:BCN1400
CAS No.:61597-55-5
- 13-Hydroxy-8,11,13-podocarpatrien-18-oic acid
Catalog No.:BCN1399
CAS No.:61597-83-9
- H-DL-Nle-OH
Catalog No.:BCC3301
CAS No.:616-06-8
- Acetylcysteine
Catalog No.:BCC3716
CAS No.:616-91-1
- (-)-Sparteine Sulfate Pentahydrate
Catalog No.:BCC8273
CAS No.:6160-12-9
- Songoroside A
Catalog No.:BCN3988
CAS No.:61617-29-6
- Amfenac Sodium Monohydrate
Catalog No.:BCC4620
CAS No.:61618-27-7
Role of oxytetracycline dihydrate in the treatment of mycoplasma-associated ovine keratoconjunctivitis in lambs.[Pubmed:7735873]
Br Vet J. 1995 Jan-Feb;151(1):83-8.
Thirty-six lambs were placed in two groups of 10 each, one group of 11 and one group of five. The first three groups were challenged with a field strain of Mycoplasma conjunctivae and the group of five lambs with an inactivated culture. One group of lambs was treated with Oxytetracycline Dihydrate as conjunctivitis developed at 1 day post-inoculation (dpi) and the other group was treated when the conjunctivitis was at its most severe (3 dpi). A rapid response to treatment was observed with a complete recovery obtained after 2 and 4 days, respectively. However, the treatment did not eliminate the M. conjunctivae infection. Conjunctivitis did not develop in the five lambs challenged with the inactivated culture.
Biological availability and in vitro dissolution of oxytetracycline dihydrate tablets.[Pubmed:22454918]
Br J Clin Pharmacol. 1974 Oct;1(5):405-8.
1 The concentration of oxytetracycline in plasma was studied by microbiological assay after oral administration of four different preparations of Oxytetracycline Dihydrate tablets. 2 There were statistically significant differences in biological availability between the four preparations, as assessed by the peak plasma level, the area under the plasma concentration-time curve, or the cumulative fraction of the dose excreted in urine at 405 minutes. In contrast, differences between the subjects were not statistically significant. 3 The differences in biological availability were not predictably related to the in vitro dissolution of the tablets.
Bioavailability of oxytetracycline dihydrate tablets in dogs.[Pubmed:7349318]
J Vet Pharmacol Ther. 1981 Mar;4(1):11-3.
Plasma oxytetracycline concentrations were studied in four healthy beagles after oral administration of four different commercial preparations of Oxytetracycline Dihydrate tablets. Although no statistically significant differences were found in the biological availability between the four tablets, assessed by the peak plasma level and the area under the plasma concentration--time curve, there was great variation in the plasma concentrations of oxytetracycline achieved in the sixteen experiments. This variation was not related to the in vitro dissolution properties of the tablets. As the amount of Oxytetracycline Dihydrate administered in the experiments was almost the maximum recommended dose and the mean peak plasma concentrations were either below or at the lower end of the therapeutic concentration range, it is suggested that higher oral doses than those officially recommended are required to attain effective plasma levels.
